corifollitropin in Medical Technology
Two Phase III clinical trials on corifollitropin alfa (Org 36286)
reach randomization target
OSS, the Netherlands, June 27, 2007-Organon, the human
healthcare business unit of Akzo Nobel, announced today that two
out of three Phase III clinical trials with corifollitropin
(Org 36286), a new long-acting fertility hormone, have reached
their randomization target.
Schering-Plough Announces Phase III Data for Sustained Follicle Stimulant
alfa meets primary endpoints in ENGAGE Trial
Corp., (NYSE: SGP ) announced today that corifollitropin
experimental, sustained follicle stimula...his
non-inferiority trial, obtained in the 150 mcg corifollitropin
treatment arm (38.9 percent per started cycle...
corifollitropin in Biological Technology
Schering-Plough Announces Phase II and III Data for Corifollitropin Alfa
Single-dose of investigational sustained follicle stimulant achieves similar efficacy to daily injections of follitropin beta given over a one week period in Phase III Study
AMSTERDAM, July 1 /PRNewswire-FirstCall/ -- Schering-Plough Corp., (NYSE: SGP ) today announced results from the Phas...
Schering-Plough Reports Financial Results for 2009 Second Quarter
...r foreign jurisdictions. (Announced June 25)
Reported results from the Phase III ENGAGE clinical trial demonstrating that a single injection of corifollitropin
alfa, first in the class of sustained follicle stimulants, achieved similar efficacy to recombinant follicle stimulating hormone (rFSH) given once dai...
Schering-Plough Completes Acquisition of Organon BioSciences
...a fast-dissolving, sublingual psychopharmacologic agent for the treatment of patients with schizophrenia and acute mania bipolar disorder; * corifollitropin
alfa (from Organon), a new fertility hormone; * Golimumab, an anti-inflammatory for the treatment of rheumatoid arthritis, psoriatic arthritis a...